Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent after the company provided an updated look at a gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.
Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.
Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
A global coalition set up to fight emerging epidemics will give $19 million to drugmaker Johnson & Johnson’s vaccine unit and Oxford University experts to work on immunizations against three major diseases.
An experimental GlaxoSmithKline vaccine could prevent tuberculosis developing in half of those who receive it, making the vaccine potentially the first new shot against the global killer in a century.
A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.
So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.